Polyglutamine androgen receptor-mediated neuromuscular disease

Cellular and Molecular Life Sciences

Volumn 73, Issue 21, 2016, Pages 3991-3999

  Giorgetti, Elisa ^a   Lieberman, Andrew P ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Androgen receptor; CAG polyglutamine disorder; Motor neuron; Skeletal muscle; Spinal and bulbar muscular atrophy

Indexed keywords

ANDROGEN RECEPTOR; GLUTAMIC ACID; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; POLYGLUTAMINE; PROLINE; SERINE; THREONINE; PEPTIDE;

CARBOXY TERMINAL SEQUENCE; DISEASE COURSE; DNA BINDING; HUMAN; KENNEDY DISEASE; LIGAND BINDING; MOTONEURON; MOTOR NEURON DISEASE; MUSCLE ATROPHY; NERVE DEGENERATION; NEUROMUSCULAR DISEASE; PATHOGENESIS; PROTEIN DNA INTERACTION; PROTEIN PROCESSING; REVIEW; SKELETAL MUSCLE; SPINAL MUSCULAR ATROPHY; ANIMAL; CHEMISTRY; METABOLISM; PATHOLOGY;

ANIMALS; HUMANS; MOTOR NEURONS; MUSCLE, SKELETAL; NERVE DEGENERATION; NEUROMUSCULAR DISEASES; PEPTIDES; RECEPTORS, ANDROGEN;

EID: 84969247929     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-016-2275-1     Document Type: Review

References (89)

1. Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30:575–621
2. La Spada AR et al (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352(6330):77–79
3. Kawahara H (1897) A family of progressive bulbar palsy. Aichi Med School J 16:3–4
4. Kennedy W, Alter M, Sung J (1968) Progressive proximal spinal and bulbar muscular atrophy of late onset. Neurology 18(7):671–680
5. Harding AE et al (1982) X-linked recessive bulbospinal neuronopathy: a report of ten cases. J Neurol Neurosurg Psychiatry 45(11):1012–1019
6. Schmidt BJ et al (2002) Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59(5):770–772
7. Sobue G et al (1993) Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 117(1–2):74–78
8. Nagashima T et al (1988) Familial bulbo-spinal muscular atrophy associated with testicular atrophy and sensory neuropathy (Kennedy–Alter–Sung syndrome). Autopsy case report of two brothers. J Neurol Sci 87(2–3):141–152
9. Battaglia F et al (2003) Kennedy’s disease initially manifesting as an endocrine disorder. J Clin Neuromuscul Dis 4(4):165–167
10. Yu Z et al (2006) Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest 116(10):2663–2672
11. Chevalier-Larsen ES et al (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24(20):4778–4786
12. Katsuno M et al (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35(5):843–854
13. Fischbeck K et al (1986) Localization of the gene for X-linked spinal muscular atrophy. Neurology 36(12):1595–1598
14. Poletti A (2004) The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front Neuroendocrinol 25:1–26
15. Clark P, Irvine R, Coetzee G (2003) The androgen receptor CAG repeat and prostate cancer risk. Methods Mol Med 81:255–266
16. Davis-Dao C et al (2012) Shorter androgen receptor CAG repeat lengths associated with cryptorchidism risk among Hispanic white boys. J Clin Endocrinol Metab 97(3):E393–E399
17. Palazzolo I et al (2008) The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol 108(3–5):245–253
18. Chang C et al (1995) Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 5(2):97–125
19. Callewaert L, Van Tilborgh N, Claessens F (2006) Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res 66(1):543–553
20. Tan EM et al (2015) Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 36(1):3–23
21. Christiaens V et al (2002) Characterization of the two coactivator-interacting surfaces of the androgen receptor and their relative role in transcriptional control. J Biol Chem 277(51):49230–49237
22. Callewaert L et al (2003) Implications of a polyglutamine tract in the function of the human androgen receptor. Biochem Biophys Res Commun 306(1):46–52
23. Bevan CL et al (1999) The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 19(12):8383–8392
24. McCampbell A et al (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9(4):2197–2202
25. Stenoien DL et al (1999) Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet 8(5):731–741
26. Rechsteiner M, Rogers SW (1996) PEST sequences and regulation by proteolysis. Trends Biochem Sci 21(6):267–271
27. Ni L et al (2013) Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor. Mol Cell Biol 33(24):4766–4778
28. Tanner TM et al (2010) A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels. Cell Mol Life Sci 67(11):1919–1927
29. Haelens A et al (2007) The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 67(9):4514–4523
30. Clinckemalie L et al (2012) The hinge region in androgen receptor control. Mol Cell Endocrinol 358(1):1–8
31. Fu M et al (2000) p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275(27):20853–20860
32. Katsuno M et al (2012) Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 99(3):246–256
33. He B et al (1999) Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274(52):37219–37225
34. Saporita AJ et al (2003) Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem 278(43):41998–42005
35. Kratter IH, Finkbeiner S (2010) PolyQ disease: too many Qs, too much function? Neuron 67(6):897–899
36. Lieberman AP et al (2014) Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep 7(3):774–784
37. Cortes CJ et al (2014) Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron 82(2):295–307
38. Adachi H et al (2005) Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 128(3):659–670
39. Yu Z et al (2006) Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. Am J Pathol 168(1):195–204
40. Wyttenbach A (2004) Role of heat shock proteins during polyglutamine neurodegeneration. J Mol Neurosci 23(1–2):69–95
41. Jochum T et al (2012) Toxic and non-toxic aggregates from the SBMA and normal forms of androgen receptor have distinct oligomeric structures. Biochim Biophys Acta 1822(6):1070–1078
42. Taylor JP et al (2003) Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 12(7):749–757
43. Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6(1):11–22
44. Li M et al (1998) Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 153(3):695–701
45. Li M et al (1998) Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 44(2):249–254
46. Miller J et al (2011) Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol 7(12):925–934
47. Montie HL et al (2009) Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 18(11)
48. Takeyama K-I et al (2002) Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35(5):855–864
49. Pratt WB, Toft DO (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood)
50. Pratt WB et al (2014) A model in which heat shock protein 90 targets protein-folding clefts: rationale for a new approach to neuroprotective treatment of protein folding diseases. Exp Biol Med 1–9
51. Pratt WB et al (2010) Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med (Maywood) 235(3):278–288
52. Pratt WB et al (2014) Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol 55:353–371
53. Pratt WB, Morishima Y, Osawa Y (2008) The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 283(34):22885–22889
54. Adachi H et al (2007) CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. Neurobiol Dis 27(19):5115–5126
55. Waza M et al (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11:1088–1095
56. Wang AM et al (2013) Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol 9:112–118
57. Van Royen ME et al (2012) Stepwise androgen receptor dimerization. J Cell Sci 125(8):1970–1979
58. Nedelsky NB et al (2010) Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 67(6):936–952
59. Orr CR et al (2010) An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem 285(46):35567–35577
60. Zboray L et al (2015) Preventing the androgen receptor N/C interaction delays disease onset in a mouse model of SBMA. Cell Rep 13(10):2312–2323
61. Lieberman AP et al (2002) Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet 11(17):1967–1976
62. Powell SM et al (2004) Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. Endocr Relat Cancer 11(1):117–130
63. Katsuno M et al (2010) Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy. J Neurosci 30(16):5702–5712
64. Sopher B et al (2004) Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 41(5):687–699
65. Minamiyama M et al (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 13(11):1183–1192
66. Butler R, Bates GP (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7(10):784–796
67. McCampbell A et al (2001) Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci USA 98(26):15179–15184
68. Steffan JS et al (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413(6857):739–743
69. Palazzolo I et al (2007) Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet 16(13):1593–1603
70. Palazzolo I et al (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63(3):316–328
71. Montie HL, Pestell RG, Merry DE (2011) SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. Neurobiol Dis 31(48):17425–17436
72. Mukherjee S et al (2009) Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. J Biol Chem 284(32):21296–21306
73. Chua JP et al (2014) Disrupting SUMOylation potentiates transactivation function and ameliorates polyglutamine AR-mediated disease. J Clin Invest
74. Sobue G et al (1989) X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112:209–232
75. Suzuki K et al (2008) CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 131(1):229–239
76. Katsuno M et al (2006) Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp Neurol 200(1):8–18
77. Suzuki K et al (2010) The profile of motor unit number estimation (MUNE) in spinal and bulbar muscular atrophy. J Neurol Neurosurg Psychiatry 81(5):567–571
78. Atsuta N et al (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129(6):1446–1455
79. Rhodes LE et al (2009) Clinical features of spinal and bulbar muscular atrophy. Brain 132(12):3242–3251
80. Sorarù G et al (2008) Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci 264(1–2):100–105
81. Chua JP et al (2014) Transcriptional activation of TFEB/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy. Hum Mol Genet 23(5):1376–1386
82. Yu Z et al (2011) Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice. PLoS Genet 7(10)
83. Rusmini P et al (2015) Aberrant autophagic response in the muscle of a knock-in mouse model of spinal and bulbar muscular atrophy. Sci Rep 5(15174)
84. Monks DA et al (2007) Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci USA 104(46):18259–18264
85. Rinaldi C et al (2012) Insulin like growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. Mol Med 18(1):1261–1268
86. Malena A et al (2013) Androgen-dependent impairment of myogenesis in spinal and bulbar muscular atrophy. Acta Neuropathol 126:109–121
87. Funakoshi H et al (1993) Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve. J Cell Biol 123(2):455–465
88. Ramzan F et al (2015) Distinct etiological roles for myocytes and motor neurons in a mouse model of Kennedy’s disease/spinobulbar muscular atrophy. J Neurosci 35(16):6444–6451
89. Sahashi K et al (2015) Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 24(21):5985–5994